spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on its Semiconductor Chip

evonetix

Researchers are invited to apply to receive DNA that has been synthesised using Evonetix’s platform


Cambridge, UK 16th August 2022
– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix’s DNA synthesis capability brings together patented semiconductor chip design and proprietary, thermally controlled synthesis chemistry, which will be integral to the Company’s future gene synthesis platforms.

Evonetix’s proprietary process utilises a novel silicon chip to control the synthesis of DNA at many thousands of independent thermally controlled reaction sites, or ‘pixels’, on the chip surface. Combined with the Company’s patented chemistry, this approach enables the accurate synthesis of thousands of sequences on a single chip to meet the demand for complex libraries and assembly of long DNA, addressing the DNA supply bottleneck in the field of synthetic biology.

Researchers are invited to apply to be included in the Company’s early access program to receive some of the first DNA prepared using its technology and demonstrate the efficacy of Evonetix DNA in routine molecular biology workflows. The Company will then look to scale up the parallel synthesis capacity of its semiconductor chips as it works toward future full commercialisation of its technology.

Matt Hayes, Founder and Chief Technology Officer at Evonetix, said: “We have been working on optimising the different elements of our technology ready to share DNA with researchers. Reaching this point in our development is a key milestone, paving the way for the expansion in scale that only semiconductor-based technologies can achieve.”

Colin McCracken, CEO of Evonetix added: “Biology is driving a revolution that will change the way we live and help solve some of the biggest problems faced by our planet today. At the core of this is the ability to deliver DNA better and faster to researchers working on these global challenges. The current model for DNA synthesis can’t deliver on the future demand for DNA. Building a platform capable of this requires highly parallel, distributed synthesis. Evonetix is ready to meet these challenges and open the door to the exciting next phase of our development.”
phone +44 1223 930300
email info@evonetix.com
web https://www.evonetix.com/
email 9a Coldham’s Business Park, Norman Way Cambridge CB1 3LH
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Cytel to Acquire SDS Life Science and SDS MedteQ to Enhance and Expand Thought-Leadership in Strategic Therapeutic Development


More info >>


White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement